Search

Your search keyword '"Lee, Chen-Fang"' showing total 366 results
Start Over Author "Lee, Chen-Fang"
366 results on '"Lee, Chen-Fang"'

2. Disadvantage of Viable Portal Vein Tumor Thrombosis in Liver Transplantation for Advanced Hepatocellular Carcinoma.

Author

Chan, Kun-Ming, Lai, Yin, Hung, Hao-Chien, Lee, Jin-Chiao, Cheng, Chih-Hsien, Wang, Yu-Chao, Wu, Tsung-Han, Lee, Chen-Fang, Wu, Ting-Jung, Chou, Hong-Shiue, and Lee, Wei-Chen

Subjects
PORTAL vein, SURVIVAL rate, CANCER relapse, RESEARCH funding, VENOUS thrombosis, LONG-term health care, TREATMENT effectiveness, CANCER patients, HEPATOCELLULAR carcinoma, LIVER transplantation, OVERALL survival, DISEASE complications
Abstract

Simple Summary: Liver transplantation (LT) is an optimal treatment option for hepatocellular carcinoma (HCC) associated with cirrhosis. Additionally, the transplantation community is eager to expand the criteria for transplantation to accommodate more patients with HCC. Despite numerous efforts to broaden LT eligibility, HCC with portal vein tumor thrombosis (PVTT) remains a contraindication due to the associated risk of poor prognosis after transplantation. However, there have been arguments addressing the dilemma of LT in cases of HCC with PVTT. This study aimed to analyze the outcomes of LT in patients with HCC and portal vein thrombosis, specifically evaluating the impact of PVTT on long-term outcomes. The results indicate that the presence of residual viable tumor within the portal vein thrombus may lead to poor outcomes following LT. Therefore, patients with HCC and PVTT could still be considered for LT after appropriate downstaging treatment. However, caution should be exercised regarding the potential for residual viable PVTT, which may result in unsatisfactory outcomes after LT. Background: Liver transplantation (LT) is a promising treatment option for patients with hepatocellular carcinoma (HCC) comorbid with cirrhosis. However, HCC with portal vein tumor thrombosis (PVTT) remains an absolute contraindication for LT. This study aimed to analyze the outcomes of LT in patients with HCC plus portal vein thrombosis and further evaluate the impact of PVTT on the long-term outcomes of patients. Methods: Among the 501 patients who underwent LT for HCC between January 2000 and March 2023, 29 (5.8%) patients with HCC who had portal vein thrombosis were further analyzed. Of these 29 patients with portal vein thrombosis, 12 (41.4%) were preoperatively diagnosed with PVTT and underwent LT after receiving downstaging therapy. The remaining 17 (58.6%) patients were PVTT-free prior to LT. Results: Overall, the recurrence-free survival rates at 1, 3, and 5 years were 96.3%, 74.2%, and 74.2%, respectively, while the 1-, 3-, and 5-year overall survival rates were 82.4%, 74.2%, and 70.1%, respectively. However, patients with viable PVTT had significantly worse outcomes than those without viable PVTT (p = 0.030). The 5-year recurrence-free and overall survival rates for patients with viable PVTT were 57.5% and 57.0%, respectively. Conclusions: LT may still be a promising option for patients with HCC and PVTT after appropriate downstaging. However, caution should be adopted, as remnant viable PVTT might lead to unsatisfactory outcomes after transplantation. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

3. Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy.

Author

Hung, Hao‐Chien, Lai, Yin, Lee, Jin‐Chiao, Wang, Yu‐Chao, Cheng, Chih‐Hsien, Wu, Tsung‐Han, Wu, Ting‐Jung, Chou, Hong‐Shiue, Chan, Kun‐Ming, Lee, Wei‐Chen, and Lee, Chen‐Fang

Subjects
OVERALL survival, LIVER transplantation, HEPATOCELLULAR carcinoma, PROGNOSIS, TUMOR surgery
Abstract

Aim: We aimed to investigate the prognostic factors for salvage liver transplant in patients with early hepatocellular carcinoma recurrence after hepatectomy. Methods: This retrospective analysis included 53 patients who underwent salvage living‐donor liver transplantation between January 2007 and January 2018. There were 24 and 29 patients in the early (recurrence ≤24 months after primary liver resection) and the late recurrence groups, respectively. Results: In the multivariate Cox regression model, pre‐liver transplant downstaging therapy, early recurrence (ER) after primary liver resection , and recurrence‐to‐liver‐transplant ≥12 months were independent risks to predict recurrent hepatocellular carcinoma recurrence after salvage living‐donor liver transplantation. Compared with the late recurrence group, the ER group showed lower disease‐free survival rates (p < 0.001); however, the overall survival rates did not differ between the two groups (p = 0.355). The 1‐, 3‐, and 5‐year disease‐free survival rates were 83.3%, 70.6%, and 66.2%, and 96.0%, 91.6%, and 91.6% in the early and late recurrence groups, respectively. When stratified by recurrence‐to‐liver transplant time and pre‐liver transplant downstaging therapy in the ER group, disease‐free survival and overall survival rates were significantly different. Conclusion: ER after primary liver resection with advanced tumor status and a longer period of recurrence‐to‐liver‐transplant (≥12 months) have a negative impact on salvage liver transplant. Our findings provide novel recommendations for treatment strategies and eligibility for salvage liver transplant candidates. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients

Author

Lee, Wei-Chen, primary, Hung, Hao-Chien, additional, Lee, Jin-Chiao, additional, Huang, Chung-Guei, additional, Huang, Po-Wei, additional, Gu, Po-Wen, additional, Wang, Yu-Chao, additional, Cheng, Chih-Hsien, additional, Wu, Tsung-Han, additional, Lee, Chen-Fang, additional, Wu, Ting-Jung, additional, Chou, Hong-Shiue, additional, and Chan, Kun-Ming, additional

Published
2023
Full Text
View/download PDF

20. Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment

Author

Chan, Kun-Ming, primary, Lai, Yin, additional, Hung, Hao-Chien, additional, Lee, Jin-Chiao, additional, Cheng, Chih-Hsien, additional, Wang, Yu-Chao, additional, Wu, Tsung-Han, additional, Lee, Chen-Fang, additional, Wu, Ting-Jung, additional, Chou, Hong-Shiue, additional, Wang, Ching-Ting, additional, Chai, Pei-Mei, additional, Lien, Hsin-Yi, additional, and Lee, Wei-Chen, additional

Published
2023
Full Text
View/download PDF

26. Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction

Author

Cheng, Chih-Hsien, primary, Hung, Hao-Chien, additional, Lee, Jin-Chiao, additional, Huang, Po-Wei, additional, Gu, Po-Wen, additional, Lai, Yin, additional, Wang, Yu-Chao, additional, Wu, Tsung-Han, additional, Lee, Chen-Fang, additional, Wu, Ting-Jung, additional, Chou, Hong-Shiue, additional, Chan, Kun-Ming, additional, Huang, Chung-Guei, additional, and Lee, Wei-Chen, additional

Published
2022
Full Text
View/download PDF

28. Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections

Author

Lai, Yin, primary, Lee, Jin-Chiao, additional, Hung, Hao-Chien, additional, Wang, Yu-Chao, additional, Cheng, Chih-Hsien, additional, Wu, Tsung-Han, additional, Lee, Chen-Fang, additional, Wu, Ting-Jung, additional, Chou, Hong-Shiue, additional, Chan, Kun-Ming, additional, Kao, Chen-Yao, additional, and Lee, Wei-Chen, additional

Published
2022
Full Text
View/download PDF

36. Potential Anticancer Effect of Celastrol on Hepatocellular Carcinoma by Suppressing CXCR4-related Signal and Impeding Tumor Growth in Vivo

Author

Lee Wei-Chen, Chou Hong-Shiue, Wu Ting-Jung, Cheng Chih-Hsien, Lee Chen-Fang, and Chan Kun-Ming

Subjects
0301 basic medicine, Receptors, CXCR4, Chemokine, Carcinoma, Hepatocellular, CXCR4, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Animals, Humans, Protein kinase B, PI3K/AKT/mTOR pathway, Cell Proliferation, biology, Cell growth, Chemistry, Liver Neoplasms, General Medicine, biology.organism_classification, Triterpenes, 030104 developmental biology, Apoptosis, Celastrol, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Tripterygium wilfordii, Pentacyclic Triterpenes, Signal Transduction
Abstract

Background Potential agents that can effectively treat hepatocellular carcinoma (HCC) are being continuously explored. Methods Celastrol extracted from roots of an ancient Chinese herb, Tripterygium wilfordii (Thunder god vine), has been identified as a potential anti-tumor agent. In this study, the molecular mechanisms underlying the action of celastrol on cell proliferation and chemokine CXCR4-related signal pathway associated with tumor growth were investigated. Results The CXCR4 expression was diminished by celastrol treatment in a dose-dependent manner, and its downstream associated pathways, including PI3K and Akt were also downregulated. Celastrol also significantly attenuated proliferation and migration ability of HCC cells, and induced cell apoptosis in vitro. Additionally, significant inhibition of HCC growth was observed in the celastrol-treated group as compared with the control group in vivo as well. Conclusion Celastrol is capable of attenuating cell proliferation and inducing apoptosis, leading to inhibition of HCC growth through the suppression of CXCR4-related signal pathway.

Published
2020
Full Text
View/download PDF

44. Preferred Treatment with Curative Intent for Left Lateral Segment Early Hepatocellular Carcinoma under the Era of Minimal Invasive Surgery

Author

Wu, Tsung-Han, primary, Wang, Yu-Chao, additional, Hung, Hao-Chien, additional, Lee, Jin-Chiao, additional, Wu, Chia-Ying, additional, Cheng, Chih-Hsien, additional, Lee, Chen-Fang, additional, Wu, Ting-Jung, additional, Chou, Hong-Shiue, additional, Chan, Kun-Ming, additional, and Lee, Wei-Chen, additional

Published
2022
Full Text
View/download PDF

45. Reconstruction of Separated Intrahepatic Ducts Using the Cystic and Common Hepatic Ducts in Right-Lobe Living-Donor Liver Transplantation: Experiences of Surgical Techniques, Biliary Complications, and Outcomes in a Single Institution

Author

Hsu, Po-Jung, primary, Hung, Hao-Chien, additional, Lee, Ching-Sung, additional, Pan, Kuang-Tse, additional, Lee, Jin-Chiao, additional, Wang, Yu-Chao, additional, Cheng, Chih-Hsien, additional, Wu, Tsung-Han, additional, Lee, Chen-Fang, additional, Chou, Hong-Shiue, additional, Chan, Kun-Ming, additional, Lee, Wei-Chen, additional, and Wu, Ting-Jung, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results